# Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

> **NCT02689453** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- T-Cell Lymphoma Relapsed
- Adult T-Cell Leukemia (ATL)
- Peripheral T-Cell Lymphoma (PTCL)
- Cutaneous T Cell Lymphoma (CTCL)
- T-Cell Prolymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** IL-15 plus
- **BIOLOGICAL:** alemtuzumab

## Key facts

- **NCT ID:** NCT02689453
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-19
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689453, "Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02689453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*